Celrixafor Injection 1's belongs to the class of hemopoietic stem cell mobilizer. It is used in the treatment of Non-Hodgkin’s Disease (a blood cancer that affects your lymph system) and multiple myeloma (a type of cancer that affects the plasma cells of the bone marrow) in combination with granulocyte-colony stimulating factor (G-CSF).
Celrixafor Injection 1's contains Plerixafor, which belongs to the hemopoietic stem cell mobilizer class or drugs. It works by binding to the chemokine receptor CXCR4 and inhibits the binding of its cognate ligand CXCL12.
Celrixafor Injection 1's may cause certain side effects, such as nausea, vomiting, headache, dizziness, diarrhoea, flatulence, fatigue, and pain at the site of injection. These side effects do not require medical attention and gradually resolve over time. A trained healthcare professional will administer it. Do not self-administer.
Avoid taking it and inform your doctor if you are allergic to Celrixafor Injection 1's or its components. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, blood disorders or respiratory conditions. This medicine is known to cause fetal harm in pregnant women. Hence, inform your doctor if you are pregnant or are planning to become pregnant. Breastfeeding should be discontinued during the treatment.